Gatifloxacin 0.3% ophthalmic solution — Competitive Intelligence Brief

Gatifloxacin 0.3% ophthalmic solution (Gatifloxacin 0.3% ophthalmic solution) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Quinolone antibiotic. Area: Infectious Disease.

phase 2 Quinolone antibiotic DNA gyrase and topoisomerase IV Infectious Disease Small molecule

Target snapshot

Gatifloxacin 0.3% ophthalmic solution (Gatifloxacin 0.3% ophthalmic solution) — Allergan. Quinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Gatifloxacin 0.3% ophthalmic solution TARGET	Gatifloxacin 0.3% ophthalmic solution	Allergan	phase 2	Quinolone antibiotic	DNA gyrase and topoisomerase IV
Cravit-based sequential therapy	Cravit-based sequential therapy	National Taiwan University Hospital	marketed	Fluoroquinolone antibiotic (as part of sequential therapy regimen)	Bacterial DNA gyrase and topoisomerase IV
Vigamox Eye Drops	Vigamox Eye Drops	Merck Sharp & Dohme LLC	marketed	Fluoroquinolone antibiotic	Bacterial DNA gyrase and topoisomerase IV
Moxifloxacin 0.5% ophthalmic solution	Moxifloxacin 0.5% ophthalmic solution	Johns Hopkins University	marketed	Fluoroquinolone antibiotic	Bacterial DNA gyrase and topoisomerase IV
Moxifloxacin HCl 0.5%	Moxifloxacin HCl 0.5%	Carolina Eyecare Physicians, LLC	marketed	Fluoroquinolone antibiotic	Bacterial DNA gyrase and topoisomerase IV
Moxifloxacin (Topical)	Moxifloxacin (Topical)	University of California, San Francisco	marketed	Fluoroquinolone antibiotic	Bacterial DNA gyrase and topoisomerase IV
Gatifloxacin 0.3%	Gatifloxacin 0.3%	Innovative Medical	marketed	Fluoroquinolone	DNA gyrase and topoisomerase IV

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Quinolone antibiotic class)

1. Allergan · 1 drug in this class
2. Ferrer Internacional S.A. · 1 drug in this class